Form 4: Mineralys CMO Sells MLYS Stock via 10b5-1 Plan
Insider Transaction Report
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 11,367 shares of common stock on September 15, 2025, through a pre-arranged 10b5-1 trading plan.
Summary
- David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc. (MLYS), reported sales of common stock.
- The transactions occurred on September 15, 2025, and were executed under a Rule 10b5-1 trading plan adopted on October 25, 2024.
- A total of 9,302 shares were sold at a weighted-average price of $35.9004 per share, with prices ranging from $35.4000 to $36.3955.
- An additional 2,065 shares were sold at a weighted-average price of $36.4748 per share, with prices ranging from $36.4026 to $36.7005.
- Following these transactions, David Malcom Rodman beneficially owns 81,524 shares of Mineralys Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing reports a pre-scheduled insider stock sale under a 10b5-1 plan, which is a routine event and typically does not imply a significant change in company prospects.
Positives
- The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates a structured and non-opportunistic approach to insider stock transactions.
Negatives
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, though this is mitigated by the pre-scheduled nature.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing reports a routine insider stock transaction and does not provide information to analyze broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Adoption of Trading Plan | Chief Medical Officer David Malcom Rodman adopted a Rule 10b5-1 trading plan on October 25, 2024, to pre-arrange stock sales. | October 25, 2024 | Enhances transparency and mitigates concerns about opportunistic insider trading by establishing a pre-scheduled plan for stock dispositions. |
Stakeholder Impact
- Shareholders: May observe insider selling, but the 10b5-1 plan context generally reduces concerns about opportunistic behavior.
Key Dates
| Date | Description |
|---|---|
| 10/25/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 09/15/2025 | Date of the reported stock transactions (sales of common stock). |
| 09/16/2025 | Date the Form 4 was signed by the Attorney-in-fact. |
Recommendation
holdThe filing details a pre-scheduled insider stock sale under a Rule 10b5-1 plan. Such transactions are generally considered routine and do not typically signal a fundamental change in the company's prospects or warrant a strong buy/sell recommendation. Investors should consider this a neutral event in the context of their broader investment thesis for Mineralys Therapeutics.
Keywords
Mineralys Therapeutics, MLYS, Insider Trading, Form 4, Stock Sale, David Malcom Rodman, Chief Medical Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.